Clinical trial
Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer
NCT00165334 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00165334 |
|---|---|
| Title | Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer |
| Official title | Phase II Trial of Cetuximab Plus Vinorelbine in Previously Untreated Patients > 70 With Advanced NSCLC |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital Brigham and Women's Hospital Beth Israel Deaconess Medical Center Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Cetuximab, Vinorelbine (Navelbine) |
| Enrollment | 53 |
| Start date | Jun 1, 2005 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Sep 14, 2005 |
| Last update posted | Jul 22, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: